Hyderabad, India, 20th May 2021: Bharat Biotech a global leader in vaccine innovation, developing vaccines for infectious diseases, announced today, the quick ramp up of additional manufacturing capacities for COVAXIN®, India’s 1st Indigenous Covid 19 Vaccine at CHIRON BEHRING Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech.
The company plans to produce 200 million doses of COVAXIN® per annum in the good manufacturing practice (GMP) facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. Product availability at Ankleshwar to commence from Q4 2021.
Bharat Biotech had already deployed multiple Production lines at its Hyderabad & Bengaluru campuses, Adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture COVAXIN®. This effectively takes the volumes upto ~ 1 Billion doses per Annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety.
The combined entity will be a boon in transforming and building India’s largest Healthcare Supply chain platform
The transaction enables Aknamed to further promote excellence in delivery of healthcare essentials, with an enhanced pan-India footprint with leadership in therapeutic areas such as oncology, immunotherapy and virology Boosted by additional investment by existing investor of Aknamed- Lightrock, part of LGT Group (a global private banking and asset management firm with over $250B assets under management), accelerating the successful completion of the transaction This is the 3rd addition to the Aknamed Group in last 12 months, scaling its business to ~$200M in annualized revenues Aknamed aims to widen its footprint to 35 locations with the ability to serve over 500 cities and towns by end of 2021 Bengaluru, may 20th, 2021: Aknamed (Akna Medical Pvt. Ltd.), India’s largest tech-enabled hospital-focused supply chain platform announced the successful transaction with Vardhman Health Specialties (Vardhman), one of the largest specialty products provider to hospitals with expertise in therapeutic areas such as oncology, immunotherapy and virology. The integrated organization with the strong proficiency in hospital focused distribution, will work towards transforming and building India’s largest healthcare supply chain platform. The transaction marks the 3rd addition to the Aknamed Group in last 12 months, scaling the business to $200M in annualized revenues. Over the next 2 years, Aknamed is aiming to invest significant additional capital to fuel the group’s organic and inorganic growth plans, while continuing to invest in people, technology and infrastructure. In fact, by the end of the current year, Aknamed will be present in 35 locations with the ability to serve over 500 cities and towns. Mr. Naresh Chowhan, CEO of Vardhman spelling out the motivation for the transaction, remarked “We are extremely pleased in partnering with Aknamed. This partnership underlines the growing importance of consolidation in the pharma supply chain industry in India. It opens up significantly larger opportunities, apart from the synergies derived from the combined businesses of Vardhman and Aknamed. The improved value proposition for our clients and stakeholders will allow us to serve them better. The combination propels us to an unequivocal leadership position to tap the large growth potential of the Indian market.” Commenting on the completion of the deal, Mr. Saurabh Pandey, Founder and CEO, Aknamed, said, “We are delighted to welcome Vardhman as part of the Aknamed Group. The vision of Aknamed has always been on delivering excellence in customer service, transparent business processes and practices with all stakeholders and developing exceptional technology based supply chain processes in niche and therapeutic areas. Our vision and goal have resonated very well with the Vardhman team as their business has been built on the similar values over the years. The focus is now to provide a top-notch supply chain service to the hospitals across country.”
Sharing his views on the completion of the transaction, Mahadevan (Mahad) Narayanamoni, Co-Founder & Chairman, Aknamed, said, “I am excited about the combination of Aknamed and Vardhman as it will solve a significant number of procurement challenges, and will broaden the horizon of healthcare supply chain in India. We also thank the continued support and guidance from our financial partners, Lightrock from LGT Group. We remain strongly committed in our endeavour to make a meaningful contribution to the digital health aspirations of hospitals in the country.”
Deloitte Corporate Finance were the exclusive financial advisors to Vardhman on the transaction
బిజెపి సీనియర్ నాయకుల పేర్లు, మాజీ గవర్నర్ పేర్లు కూడా సమీక్షించబడ్డాయి – ప్రత్యేక గవర్నర్లను కలిగి ఉండటానికి తెలంగాణ మరియు ఎపి. మాజీ చీఫ్ అనిల్ కుమార్ దాస్మాన మాట్లాడుతూ శ్రీ. శాంత్ కుమార్ నియామకం శ్రీ. ఉమా భారతి, శ్రీ.ప్రేమ్ కుమార్ ధుమాల్ మరియు ఇతర రిటైర్డ్ అధికారులు సాధ్యమవుతారు. రీసెర్చ్ అనాలిసిస్ వింగ్ (రా), మాజీ ఐబి చీఫ్లు రాజీవ్ జైన్, దినేశ్వర్ శర్మ, మాజీ సిఇసి ఎకె జ్యోతి వేర్ కూడా పరిశీలనలో ఉన్నారు. చాలా మంది గవర్నర్లు మారతారని భావిస్తున్నారు.
ಕೋವಿಡ್ ಹಿನ್ನೆಲೆಯಲ್ಲಿ ಅನಾಥವಾದ ಮಕ್ಕಳ ಪೋಷಣೆಗೆ ಸರ್ಕಾರ ಸಿದ್ದ – ಬಾಧಿತ ಮಕ್ಕಳ ವಸತಿಗಾಗಿ ರೆಸಿಡೆನ್ಸಿಯಲ್ ಶಾಲೆ ಮೀಸಲು – ಸಚಿವೆ ಶಶಿಕಲಾ ಜೊಲ್ಲೆ ಮಹತ್ವದ ಘೋಷಣೆ
ಬೆಂಗಳೂರು ಮೇ.18 – ರಾಜ್ಯದಲ್ಲಿ ಕೋವಿಡ್ ಎರಡನೇ ಅಲೆ ಹಿನ್ನೆಲೆಯಲ್ಲಿ ಪಾಲಕರ ಪೋಷಣೆಯಿಂದ ಅನಾಥರಾದ ಮಕ್ಕಳ ಪುನರ್ವಸತಿ ಕಲ್ಪಿಸಲು ಸರ್ಕಾರ ಸಿದ್ದವಿದ್ದು, 18 ವರ್ಷದೊಳಗಿನ ಮಕ್ಕಳ ಕ್ವಾರೆಂಟೈನ್ ಗಾಗು ಒಂದು ವಸತಿಶಾಲೆ ನಿರ್ಧರಿಸಲಾಗಿದ್ದು, ಅಂಥಹ ಮಕ್ಕಳ ಯಾವುದೇ ಕಾರಣಕ್ಕೂ ಭಯ ಪಡುವ ಅವಶ್ಯಕತೆ ಇಲ್ಲ ಎಂದು ಮಹಿಳಾ ಮತ್ತು ಮಕ್ಕಳ ಕಲ್ಯಾಣ ಸಚಿವೆ ಶ್ರೀಮತಿ ಶಶಿಕಲಾ ಜೊಲ್ಲೆ ಅಭಯ ನೀಡಿದ್ದಾರೆ.
ಕೋವಿಡ್ ಕಾರಣದಿಂದ ಅನಾಥರಾದ ಮಕ್ಕಳ ಕುರಿತು ಮಹಿಳಾ ಮತ್ತು ಮಕ್ಕಳ ಅಭಿವೃದ್ಧಿ ಇಲಾಖೆ ಕೈಗೊಂಡ ಕ್ರಮಗಳ ಕುರಿತು ಮಾಹಿತಿ ನೀಡಿದ ಅವರು, ಕೋವಿಡ್ ನಿಂದ ಬಾಧಿತರಾದ ಮಕ್ಕಳನ್ನು ಗುರುತಿಸಲು ಹಾಗೂ ಪುನರ್ವಸತಿಗೆ ಸರ್ಕಾರ 1098 ಎಂಬ ಸಹಾಯವಾಣಿ ತಂದಿದ್ದು, ಹಿರಿಯ ಐಎಎಸ್ ಅಧಿಕಾರಿ ಮೋಹನ್ ರಾಜ್ ಅವರನ್ನು ನೋಡಲ್ ಅಧಿಕಾರಿಯಾಗಿ ನೇಮಿಸಲಾಗಿದ್ದು, ಇಂಥ ಮಕ್ಕಳಿಗೆ ಕೌಟುಂಬಿಕ ವಾತಾವರಣ ಒದಗಿಸುವುದು ಸಚಿವೆಯಾಗಿ ನನ್ನ ಹಾಗೂ ನಮ್ಮ ಇಲಾಖೆ ಹಾಗೂ ನಮ್ಮ ಸರ್ಕಾರದ ಕರ್ತವ್ಯ ಎಂದರು.
ಮಕ್ಕಳು ಪಾಲಕರ ಪೋಷಣೆಯಿಂದ ವಂಚಿರಾಗುವ ಸಂಧರ್ಭಗಳು
1.ತಂದೆ – ತಾಯಿ ಕೋವಿಡ್ ನಿಂದ ಮೃತರಾದರೆ 2.ತಂದೆ-ತಾಯಿ ಇಬ್ಬರು ಆಸ್ಪತ್ರೆಗೆ ದಾಖಲಾದರೆ
ಕೋವಿಡ್ ನಿಂದ ಒಬ್ಬರು ಮೃತರಾಗಿ ಇನ್ನೊಬ್ಬರು ಆಸ್ಪತ್ರೆಗೆ ದಾಖಲಾದರೆ
ಒಬ್ಬರು ಮೃತರಾಗಿ ಇನ್ನೊಬ್ಬರು ಬೇರೆ ಪ್ರದೇಶದಲ್ಲಿ ವಾಸವಿದ್ದರೆ. ಈ ಮೇಲಿನ ಕಾರಣಗಳಿಂದ ಮಕ್ಕಳು ಅನಾಥರಾದಾಗ ಅವರಿಗೆ ನಾವಿದ್ದೇವೆ ಎಂಬ ಭಾವನೆಯನ್ನು ಮೂಡಿಸಲು ಇಲಾಖೆ ಸಜ್ಜಾಗಿದೆ.
ಇನ್ನು ಸಚಿವೆ ಶಶಿಕಲಾ ಜೊಲ್ಲೆಯವರ ವಿಶೇಷ ಮುತುವರ್ಜಿ ಮೇರೆಗೆ ಕೋವಿಡ್ ಬಾಧಿತ ಅನಾಥ ಮಕ್ಕಳಿಗಾಗಿಯೇ ಹಲವು ಯೋಜನೆಗಳನ್ನು ಜಾರಿಗೆ ತರಲಾಗಿದೆ.
6 ವರ್ಷದೊಳಗಿನ ಮಕ್ಕಳ ಆರೈಕೆಗೆ ವಿಶೇಷ ಕ್ವಾರೆಂಟೈನ್ ಸೌಲಭ್ಯ, ವಿಶೇಷ ದತ್ತು ಸಂಸ್ಥೆಗಳನ್ನು ಗೊತ್ತುಪಡಿಸುವುದು.
7 ರಿಂದ 18 ವರ್ಷದೊಳಗಿನ ಮಕ್ಕಳ ಆರೈಕೆಗೆ ವಿಶೇಷ ಕ್ವಾರೆಂಟೈನ್ ಸೌಲಭ್ಯ ಹಾಗೂ ಪಿಟ್ ಫೆಸಿಲಿಟಿಸ್ ಒದಗಿಸುವುದು
18 ವರ್ಷದವರೆಗಿನ ಮಕ್ಕಳ ಕ್ವಾರೆಂಟೈನ್ ಗಾಗಿ ರೆಸಿಡೆನ್ಸಿಯಲ್ ಮೀಸಲಿಡಲು ತೀರ್ಮಾನ
ಕೋವಿಡ್ ಸೋಂಕಿತ ಮಕ್ಕಳ ಚಿಕಿತ್ಸೆಗೆ ವಿಶೇಷ ಯೋಜನೆ
ಯಾವುದೇ ಲಕ್ಷಣಗಳಿಲ್ಲದ ಕೋವಿಡ್ ಪೀಡಿತ ಮಕ್ಕಳಿಗೆ ವಿಶೇಷ ಪಿಡಿಯಾಟ್ರಿಕ್ ಕೋವಿಡ್ ಕೇರ್ ಸೆಂಟರ್ (CCC) ಗಳಲ್ಲಿ ಚಿಕಿತ್ಸೆ ನೀಡಲು ಅನುಕೂಲವಾಗುವಂತೆ 30 ಜಿಲ್ಲೆಗಳಲ್ಲಿ ಪ್ರತ್ಯೇಕ ಕೋವಿಡ್ ಕೇರ್ ಸೆಂಟರ್ ಸ್ಥಾಪನೆ 2.ಲಕ್ಷಣವುಳ್ಳ ಕೋವಿಡ್ ಸೋಂಕಿತ ಮಕ್ಕಳಿಗೆ ತಾಲೂಕು ಹಾಗೂ ಜಿಲ್ಲಾ ಆಸ್ಪತ್ರೆಯಲ್ಲಿ ಪಿಡಿಯಾಟ್ರಿಕ್ ಕೋವಿಡ್ ಕೇರ್ ಸೆಂಟರ್ ನಲ್ಲಿ ವಿಶೇಷ ಆರೈಕೆ. ಇಲಾಖೆಯಿಂದ ವಿಶೇಷ ಆರೈಕೆದಾರರ ನೇಮಕ
ಕೋವಿಡ್ ಸಂಧರ್ಭದಲ್ಲಿ ನಮ್ಮ ಇಲಾಖೆಯಿಂದ ಕೈಗೊಂಡ ಕ್ರಮಗಳು
ಅಂಗನವಾಡಿ ಫಲಾನುಭವಿಗಳಿಗೆ ಮನೆಮನೆಗೆ ತೆರಳಿ ವಿಶೇಷ ಪೌಷ್ಟಿಕ ಆಹಾರ ವಿತರಣೆ 2.ಅಂಗನವಾಡಿ ಮಕ್ಕಳು, ಗರ್ಭಿಣಿ, ಬಾಣಂತಿಯರ ಆರೋಗ್ಯದ ಮೇಲೆ ವಿಶೇಷ ನಿಗಾ
ಕೋವಿಡ್ ಸೋಂಕಿನಿಂದ ಮರಣಹೊಂದಿದ 12 ಅಂಗನವಾಡಿ ಕಾರ್ಯಕರ್ತೆಯರಿಗೆ 30 ಲಕ್ಷ ರೂಗಳ ಪರಿಹಾರ ಬಿಡುಗಡೆಗೆ ಕ್ರಮ ಕೈಗೊಳ್ಳಲಾಗಿದೆ.
3ನೇ ಅಲೆಯು ಚಿಕ್ಕ ಮಕ್ಕಳಲ್ಲಿಯೇ ಹೆಚ್ಚಾಗಿ ಸೋಂಕು ಕಂಡುಬರುತ್ತದೆ ಎಂದು ತಜ್ಞರು ಎಚ್ಚರಿಸಿದ ಹಿನ್ನೆಲೆಯಲ್ಲಿ ಈಗಾಗಲೇ ನಮ್ಮ ಇಲಾಖೆ ಇದಕ್ಕೆ ಪೂರಕವಾದ ಕ್ರಮಗಳನ್ನು ಕೈಗೊಳ್ಳುತ್ತಿದೆ.
Home-grown VIRANORM’ shows breakthrough results in reduction of NL Ratio and increase of cellular immunity in fight against COVID-19.
The Bengaluru based Khoday Group of Industries has rolled out a first of its kind Ayurvedic Immuno-modulator VIRANORM that helped COVID patients recover quickly in a recently coneluded clinical trial. With ViraNorm’, the Khoday Group is making its entry into the field of science-based alternative medicine.
*ViraNorm’ approved by AYUASH has been developed by the Khoday Group in collaboration with Althea DRF Life Sciences: ViraNorm has undergone one of the largest randomized multicentre phase 3 clinical trials in the country for an Ayurvedic formulation. This trial was conducted in leading institutions like Vietoria hospital, Bengaluru, and was carried out in line with international standards for clinical trials.
ViraNorm’ was developed post extensive safety and efficacy studies, and was found to be effective in the clinical trial” says Dr. Manu Jaggi COO, Althea DRF Lifesciences. *ViraNorm helps halt the progression of virus in the body. “ViraNorm’ can therefore be referred to as an add-on therapy/medication for asymptomatic and mildly symptomatic COVID patients. ViraNorm helps in stopping the migration of the patients from mild to moderate condition.
“Neutrophil- Lymphocyte Ratio (NI R) has increasingly come under spotlight as a very useful, rapid and inexpensive prognostic biomarker for COVID-19 patients. where elevated NLR levels may be associated with unfavourable clinical prognosis. In COVID-19 infections, low NLR levels (ratio range between 0.75-3 is considered as normal) may indicate lower inflammation and higher cytotoxic T cell immunity, and may signify lower COVID-19 viral loads, and may aid in better recovery”, says Dr. Radheshyam Naik, a leading Doctor, and the Prineipal Investigator of the ViraNorm clinical trial.
Human body fights against diseases by showing two types of immunities. One, is antibody mediated immunity. and the other is cell mediated immunity”. The newly developed Ayurvedic medicinal product ViraNorm’ was proven to improve the patients’ cell mediated immunity in the clinical trial, thereby helping patients to recover faster.
Further, it was proven in the clinical trial, that, ViraNorm” also reduces both the duration and the severity of cough and breathlessness significantly, which are the primary symptoms of COVID patients. The ingredients in the capsule work by not letting the adhesion of the virus to the cell surface of the individual in nasal or oral cavity regions.
“The reduced NLR ensures reduction in Cellular Level Inflammation and increases Cell Mediated Immunity. This is the only alternative medication which has been systematically proven to reduce NLR in a clinical trial. Since this is developed on fundamental basis of immunity, it may work even for variants of the virus,” says Dr K.G.Padmanaban, who has formulated ViraNorm’.
Human body fights against diseases by showing two types of immunities. One, is *antibody mediated immunity’, and the other is cell mediated immunity. The newly developed Ayurvedic product ViraNorm’ was proven to improve the patients’ cell mediated immunity in the clinical trial, thereby helping patients to recover faster.
Further, it was proven in the clinical trial that ViraNorm’ also reduces both the duration and the severity of cough and breathlessness significantly, which are the primary symptoms of COVID patients.
Swamy Khoday Vice Chairman and Managing Director, Khoday Group of Industries says, “ViraNorm‘, which is found to be very effective in clinical trial, and all the technical details are well cireulated.
“I firmly believe that medicines made out of natural ingredients backed by scientific principles will assist in getting cured from ailments and maintain health with no adverse effects”, Swamy points out.
The Clinical Trial for ViraNorm’ was done in Victoria Hospital and other institutions of Bengaluru, which are NABH (National Accreditation Board for Hospitals) accredited. The trial was done with the approval of CTRI (Clinical Trials Registry- India). For this 250 COVID subjects were randomized and enrolled for the trial that lasted for 6 months. These 250 patients were divided into two arms of 125 cach. One group was administered the ViraNorm’ and other was not. After a detailed analysis of the trial it was found, that those who were administered ViraNorm fared better compared to those who were not administered this medicine.
“Very interestingly, this promotion of T cell immunity and reduction of cellular inflammation seems to be in both younger (less than 40 years), as well as older (more than 60 years) patients. While older patients have always been a vulnerable age group, the ongoing 2nd wave of COVID-19 is also affecting younger patients in large numbers and therefore this observation seems important”, says Rajeev Nagi. a leading healthcare industry expert.
The enhanced Cell Immunity plays its role in long term recovery. ‘ViraNorm’ is also safe for patients suffering from comorbidities such as hypertension and diabetes.
ViraNorm‘ is available at LK Wellness Centre (#75, 3rd Cross, Residency Road, Bengaluru- 560025) and can be contacted on 080-40934216/93801 74977. ViraNorm is priced at Rs 2000/- per bottle of 60 capsules.
You must be logged in to post a comment.